(Q38827600)

English

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l

scientific article published on 16 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l (English)

1 reference

Europe PubMed Central

6 September 2017

Burkitt lymphoma

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Aradhana Awasthi

1

1 reference

Europe PubMed Central

6 September 2017

Janet Ayello

2

1 reference

Europe PubMed Central

6 September 2017

Carmella Van de Ven

3

1 reference

Europe PubMed Central

6 September 2017

Mona Elmacken

4

1 reference

Europe PubMed Central

6 September 2017

Anthony Sabulski

5

1 reference

Europe PubMed Central

6 September 2017

Matthew J Barth

6

1 reference

Europe PubMed Central

6 September 2017

Myron S Czuczman

7

1 reference

Europe PubMed Central

6 September 2017

Humayun Islam

8

1 reference

Europe PubMed Central

6 September 2017

Christian Klein

9

1 reference

Europe PubMed Central

6 September 2017

Mitchell S Cairo

10

1 reference

Europe PubMed Central

6 September 2017

language of work or name

0 references

publication date

16 October 2015

1 reference

Europe PubMed Central

6 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

6 September 2017

171

1 reference

Europe PubMed Central

6 September 2017

5

1 reference

Europe PubMed Central

6 September 2017

763-775

1 reference

Europe PubMed Central

6 September 2017

The future role of monoclonal antibody therapy in childhood acute leukaemias

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Anti-CD20 monoclonal antibodies: historical and future perspectives

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

The current status and future impact of targeted therapies in non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.13764

21 January 2018

Identifiers

10.1111/BJH.13764

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38827600&oldid=1719458826"